secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001213900-23-059049
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics appoints Robert Lisicki to Board of Directors
-------------------------------------------------------------------

- Robert Lisicki appointed as Class II director effective July 23, 2023; Board expanded from four to five seats.
- Lisicki brings over 25 years pharma experience, including CCO at Arena Pharmaceuticals through its $6.7B sale to Pfizer.
- He will receive $35,000 annual fee and 75,000 stock options vesting 1/3 on Aug 1, 2024 then monthly over 24 months.
- Lisicki also joins Compensation and Nominating/Governance Committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390023059049/0001213900-23-059049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390023059049/ea182217-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-059049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer